Orthofix Q2 Sales Rise 5%, Raises Full-Year Guidance; CMS Reimbursement Restored
OFIX sits 51% above its 52-week low of $8.85.
Summary
Orthofix Medical reported Q2 2026 net sales of $210.9M, up 5% on a pro forma constant currency basis, and raised full-year 2026 guidance. CMS restored Medicare reimbursement for bone growth stimulators, removing a temporary headwind.
Key Events · Earnings and Guidance · OFIX
-
Q2 Revenue Beats, Guidance Raised
Net sales of $210.9M grew 5% pro forma constant currency. Full-year 2026 guidance raised for both revenue and adjusted EBITDA, reversing the May guidance cut.
-
CMS Reimbursement Restored
On July 1, 2026, CMS withdrew May 2026 billing changes for bone growth stimulators, restoring prior reimbursement rates. This removes a temporary pricing headwind for the Therapeutic Solutions segment.
-
Gross Margin Expands to 71%
Gross margin improved 230 bps year-over-year to 71.0%, driven by lapping M6 product line discontinuation charges and higher sales volumes.
-
Cash Burn Continues
Operating cash flow was negative $23.8M in H1 2026, worse than the $6.8M used in H1 2025, driven by working capital build and litigation settlement payments. Cash balance stands at $103.8M.
Analysis · OFIX · Industrial Applications And Services
A solid quarter for Orthofix, with 5% pro forma constant currency revenue growth, prompted an upward revision to the full-year outlook for both revenue and adjusted EBITDA. Gross margin expanded to 71%, helped by the absence of last year's heavy M6-related impairment charges. The July 1 CMS reversal of bone growth stimulator reimbursement cuts removes a key overhang that had pressured Therapeutic Solutions pricing in Q2. Cash burn remains a concern — operations used $23.8M in the first half — but the company holds $103.8M in cash and has access to additional credit. The raised guidance and regulatory tailwind are the main stories here.
At the time of this filing, OFIX was trading at $13.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $493.1M. The 52-week trading range was $8.85 to $16.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.